Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
BioDelivery Sciences International Inc Market Cap
Based on ratings from 7 stock analysts, the BioDelivery Sciences International Inc stock price is expected to decrease by 3.76% in 12 months. This is calculated by using the average 12-month stock price forecast for BioDelivery Sciences International Inc. The lowest target is $3.64 and the highest is $6. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assigned BDSI 7 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect BioDelivery Sciences International Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BDSI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of BDSI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Amsellem Piper Sandler | Neutral | $5.6 | Downgrade | Feb 15, 2022 |
| Oren Livnat HC Wainwright & Co. | Neutral | $4.5 | Maintains | Jan 21, 2022 |
| Oren Livnat HC Wainwright & Co. | Neutral | $4.5 | Downgrade | Nov 4, 2021 |
| Oren Livnat HC Wainwright & Co. | Buy | $6 | Maintains | Aug 5, 2021 |
| Oren Livnat HC Wainwright & Co. | Buy | $5.5 | Maintains | Mar 11, 2021 |
SunTrust Robinson Humphrey | Buy | $9 | Maintains | Dec 18, 2019 |
SunTrust Robinson Humphrey | Buy | Initiates | Mar 20, 2019 | |
| Oren Livnat HC Wainwright & Co. | Buy | $3.5 | Maintains | May 23, 2018 |
H.C. Wainwright | Buy | Maintains | May 23, 2018 | |
Seaport Global | Buy | Initiates | Jan 26, 2018 | |
Cantor Fitzgerald | Overweight | Upgrade | May 17, 2017 | |
Janney Montgomery Scott | Buy | Upgrade | Sep 23, 2016 | |
Janney Capital | Buy | Upgrade | Sep 23, 2016 | |
Cantor Fitzgerald | Hold | $5 | Downgrade | May 11, 2016 |
Roth Capital | Buy | $9 | Maintains | Mar 11, 2016 |
Cantor Fitzgerald | Buy | Initiates | Nov 4, 2015 | |
Cantor Fitzgerald | Buy | $12 | Maintains | May 12, 2015 |
FBR Capital | Outperform | $18 | Maintains | May 12, 2015 |
Cantor Fitzgerald | Buy | Initiates | Apr 8, 2015 | |
FBR Capital | Outperform | Initiates | Apr 2, 2015 |
When did it IPO
2002
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$577.1M
In 2023, BDSI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BDSI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 18 Mar 2022
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have been compared to their sector's performance year-to-date. Further details on specific performance metrics were not provided.
Why It Matters - Performance comparisons reveal relative strength or weakness of BDSI and VRTX against their sector, influencing investment decisions and portfolio adjustments.
Wed, 02 Mar 2022
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - BioDelivery (BDSI) is expected to fall short of a likely earnings beat in its upcoming report due to a lack of key ingredients for positive performance.
Why It Matters - BioDelivery's lack of the right ingredients for an earnings beat may signal weak performance, potentially affecting stock price and investor sentiment.
Thu, 24 Feb 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - An FDA-approved oral solution for acute migraine treatment in adults is now available, providing a new option for patients with or without aura.
Why It Matters - The FDA approval of a novel migraine treatment could boost sales for the company, attract investment, and influence market dynamics in the pharmaceutical sector.
Thu, 24 Feb 2022
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - A golden cross event in a stock indicates a potential bullish trend, suggesting investors may consider this a favorable signal for buying or holding.
Why It Matters - A golden cross indicates potential bullish momentum, suggesting rising stock prices, which may attract more investors and drive demand, positively impacting market sentiment.
Tue, 15 Feb 2022
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - Rigrodsky Law is investigating BioDelivery Sciences (NASDAQ: BDSI) for potential fiduciary duty breaches related to its acquisition by Collegium Pharmaceutical, offering $5.60 per share.
Why It Matters - The investigation into BioDelivery's acquisition may indicate potential legal issues, impacting shareholder value and raising concerns about the deal's legitimacy and future stock performance.
Wed, 16 Feb 2022
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Former Louisiana Attorney General Charles C. Foti, Jr. has made headlines, but the specific context or implications for investors are not provided in the excerpt.
Why It Matters - The mention of a former Attorney General could signal potential legal implications or regulatory changes that may affect local businesses and investments in Louisiana.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
